CMS has updated its list of authorized compendia that may be used in determining medically-accepted indications of drugs and biologicals used off-label in an anti-cancer chemotherapeutic regimen under Medicare Part B. Specifically, CMS will add Elsevier Gold Standard’s Clinical Pharmacology compendium to the list of Medicare anti-cancer treatment compendia. Earlier this year, CMS approved the NCCN Drugs & Biologics Compendium and Thomson Micromedex DrugDex. More information is available here.